ACT has demonstrated to cure and prevent PTLD, and has shown to be highly effective in the treatment of NPC and HL by targeting latent proteins EBNA1, LMP1/LMP2. The gene discussed is PSMB9; the disease is post-transplant lymphoproliferative disease.